After this afternoon's -3.2% drop to $236.59 per share, AbbVie might just keep moving past its target price of $227.78. With an average analyst rating of buy, and target prices from $184.0 to $270.0, the stock's next move is anyone's guess.
AbbVie's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.9%. The stock's short ratio is 3.6. At 0.1%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 74.6%. In conclusion, we believe there is mixed market sentiment regarding AbbVie.
Institutions Invested in AbbVie
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 10% | 177,298,707 | $41,947,100,439 |
| 2025-06-30 | Blackrock Inc. | 8% | 147,456,064 | $34,886,629,641 |
| 2025-06-30 | State Street Corporation | 5% | 80,024,129 | $18,932,908,387 |
| 2025-06-30 | JPMORGAN CHASE & CO | 3% | 57,214,407 | $13,536,356,342 |
| 2025-06-30 | Morgan Stanley | 2% | 41,700,001 | $9,865,803,083 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 39,178,351 | $9,269,205,919 |
| 2025-06-30 | Laurel Wealth Advisors LLC | 2% | 30,741,000 | $7,273,013,077 |
| 2025-06-30 | Charles Schwab Investment Management, Inc. | 2% | 26,783,329 | $6,336,667,710 |
| 2025-06-30 | Capital Research Global Investors | 1% | 25,265,579 | $5,977,583,243 |
| 2025-06-30 | Bank of America Corporation | 1% | 25,109,645 | $5,940,690,818 |
